15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering PAVmed Inc, 1 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $57.00 to $57.00, so the covering firms are broadly aligned. The average target of $57.00 sits 1090% above the current $4.79. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.64 next quarter toward $-2.38 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Strong Buy
Strong Buy00%
Buy1100%
Hold00%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to PAVmed Inc.
As of Sep, 1 of 1 firms rate PAVM a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
PAVM EPS & revenue forecast
EPS · NEXT QUARTER
$-0.64
Range $-0.64 – $-0.64 · 1 analysts · -39% YoY
Next period, 1 analysts expect PAVmed Inc to earn $-0.64 a share (range $-0.64 – $-0.64), versus $-1.05 a year earlier. Full-year consensus is $-2.33, growing to $-2.38 the year after.
REVENUE · NEXT QUARTER
$130.0K
Range $60.0K – $200.0K · 1 analysts · +150% YoY
Revenue is expected to reach $130.0K (range $60.0K – $200.0K), +150.0% year-over-year. Full-year consensus is $232.5K, rising to $600.0K next year.
Top analysts covering PAVmed Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PAVM.
#1
Edward Woo
Ascendiant Capital · Rank #430
Buy
$57.00+1090.0% to target
Overall win rate
26%
+ Follow
PAVM stock forecast FAQ
What is PAVM's average 12-month price target?+
The 1 analysts with a live target average $57.00 for PAVmed Inc over the next 12 months, ranging from a $57.00 high to a $57.00 low.
Is PAVM stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 1 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover PAVM?+
1 analysts have an active rating on PAVmed Inc, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering PAVM?+
Among analysts who currently cover PAVM, Edward Woo of Ascendiant Capital has the strongest overall Quantellect track record (Rank #430). Their current call is Buy with a $57.00 target.
What is PAVmed Inc's projected EPS for next quarter?+
The consensus estimate is $-0.64 per share (range $-0.64 – $-0.64) across 1 analysts. Full-year EPS is projected at $-2.33, rising to $-2.38 the following year.
How much revenue is PAVmed Inc expected to report next quarter?+
Consensus revenue is $130.0K (range $60.0K – $200.0K). Full-year revenue is projected at $232.5K, growing to $600.0K next year.
Have analysts been upgrading or downgrading PAVM lately?+
As of Sep, 1 of 1 firms rate PAVM a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PAVM calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
